Pharma & medical
Make credible sustainability claims across your pharmaceutical & medical device portfolio
PRé helps pharmaceutical and medical device companies understand the environmental impacts of their products, value chains and care solutions, so they effectively reduce the environmental impact, make better decisions, reduce risks, and communicate sustainability with confidence.
Industry challenges
Sustainability in the pharmaceutical and medical technology sectors is complex and rapidly evolving. For many companies, keeping pace with these developments remains a challenge. Key issues includes:
- High volumes of waste and associated environmental impacts from wastewater and single-use materials
- Strong dependence on scope 3 data with limited availability of primary data
- Constantly evolving methodologies across standards and initiatives
- Increasing regulatory scrutiny and audit pressure on sustainability claims
- Growing procurement requirements for verified and comparable product, portfolio or care pathway LCA and carbon data
How we support pharmaceutical and medical companies
PRé combines in-depth LCA expertise accross methodologies, software, and policy, with strategic foresight tailored to the complex value chains of the pharmaceutical and medical technology sectors.
We support you with:
Environmental footprinting and scenario analysis
Using scenario analysis, we help you design and evaluate care pathway choices, including material selection, reuse, remanufacturing, recycling, and substance-specific wastewater impacts. This supports the integration of ecodesign principles early in development to reduce environmental impacts and costs early on.
Portfolio level analysis
Compare products and care pathways, identify hotspots, and support decision making in your portfolio. Embed LCA into your organization and turn one-off studies into scalable internal LCA capability and competitive advantage.
Methodology development
Align with relevant standards, develop internal environmental footprinting guidelines, and contribute to sector methodologies (e.g., PEFCRs or PCRs). We combine LCA expertise with stakeholder engagement to support harmonisation and comparability.
LCA Tool development and integration
Build scalable LCA systems and integrate environmental assessment into internal processes and decision-making.
Strategic foresight and roadmap development
Anticipate policy and market developments in environmental footprinting to stay ahead of regulatory and competitive shifts. We help you translate emerging requirements into actionable roadmaps, so your internal LCA systems remain resilient, future-proof, and aligned with where your industry is heading.
Why PRé
- Over 35 years of experience in LCA
- Trusted by global brands and sustainability leaders
- Unique combination of consulting expertise and leading LCA software (SimaPro)
- Deep expertise in product, portfolio, and care pathway sustainability across complex value chains
Case studies
Methodological developments
PCF guidelines for biopharma
Client: BioPhorum
Recommendations and a roadmap were developed for Product Carbon Footprint (PCF) guidelines covering supplies used in biologics manufacturing.
PCRs for assistive products
Client: Care Resources Protocol (CRP)
Development of PCR and complementary PCRs for assistive and mobility products, including wheelchairs, medical beds, lifting aids, and walking devices.
Healthcare pathway methodologies
Collaborative academic initiative
Development of methodologies to assess the environmental impact of healthcare pathways and support sustainability in clinical and policy decisions.
LCA Experiences
Eco-design LCA tool for medical pen injectors
Client: Owen Mumford
An LCA-based scenario tool was developed to help assess the environmental footprint of medical pen injectors and identify lower-impact design opportunities.
ISO-conform LCA studies for medical devices
Client: Owen Mumford
Three externally reviewed life cycle assessments were conducted for medical devices in accordance with ISO 14040 and ISO 14044 standards.
Schedule a consultation
Marina Dumont
Sector Lead Medical & Pharma
Marina Dumont leads Life Cycle Assessment (LCA) initiatives for pharmaceuticals and medical devices at PRé Sustainability. She is an experienced LCA consultant specializing in environmental footprinting, including Product Environmental Footprint (PEF), methodological development and harmonization, and compliance analysis. Marina currently collaborates with the European Commission and medical sector associations to develop harmonized LCA methodologies for healthcare products.